Synchron Closes $340M Series E to Accelerate Stentrode Commercialization in the US and EU

Synchron announced today the close of a $340 million Series E funding round, marking one of the largest single financings in brain-computer interface history and signaling continued institutional confidence in the minimally invasive BCI segment. The round was led by Andreessen Horowitz Bio Fund with participation from Khosla Ventures, ARCH Venture Partners, and several undisclosed strategic investors from the medical device sector.

Scaling Manufacturing and Clinical Operations

The New York and Melbourne-based company will deploy the capital primarily toward scaling commercial manufacturing of its Stentrode device, expanding its clinical and regulatory affairs teams, and building out the reimbursement infrastructure necessary for broad adoption in both US and European markets. Synchron received FDA Breakthrough Device Designation several years ago, and the company confirmed today that its pivotal trial data submission remains on track for the fourth quarter of 2026.

Unlike cortical implant competitors that require open-brain surgery, Synchron's Stentrode is delivered endovascularly through the jugular vein and seated in the superior sagittal sinus adjacent to the motor cortex. The approach eliminates craniotomy, a distinction the company argues is central to reaching the broader population of patients with ALS, spinal cord injury, and stroke who may not qualify for or consent to more invasive procedures. CEO Tom Oxley stated that the funding will allow Synchron to move from a "proof-of-concept phase into a genuine healthcare business" within the next 18 months.

Competitive Landscape and Reimbursement Challenges

The announcement arrives at a pivotal moment for the BCI industry overall. Neuralink continues its own US pivotal trial enrollment, while Precision Neuroscience reported expanded placements of its Layer 7 cortical array earlier this year. The competitive landscape is intensifying, but analysts note that each platform is pursuing somewhat differentiated patient populations and clinical indications, leaving room for multiple commercial winners in what researchers project will be a $6.2 billion global BCI market by 2031.

Reimbursement remains the most significant unresolved variable for the entire sector. Synchron confirmed it is in active dialogue with CMS regarding a potential new-technology add-on payment pathway, a process that typically spans 12 to 24 months. Parallel conversations are underway with NICE in the United Kingdom and health technology assessment bodies in Germany and France.

Industry observers will be watching Synchron's regulatory submission closely, as an FDA clearance or approval decision would represent a defining commercial milestone not just for the company but for the minimally invasive BCI category as a whole.